Visit our website: http://bit.ly/2GtXaiw
Selin Kurnaz, Co-founder & CEO, Massive Bio
Abstract:
Massive Bio (https://massivebio.com/) is an artificial intelligence powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information to speed up drug development. Massive Bio tackles a $39 billion market to speed up oncology drug development while disrupting oncology research. Massive Bio “controls” patient enrollment value chain from patient identification through outcomes collection. Massive Bio tackles “last mile” issues in site identification/out of pocket costs for patients, incremental to our world class AI based technology, real world data analytics and patient engagement capabilities. Massive Bio has just launched a hub to assemble the largest artificial intelligence enabled just-in-time precision oncology clinical trial network in the world. In this discussion, the co-founder and CEO, will provide company introduction and the ways how Massive Bio substantially increases oncology trial enrollment rates and significantly differentiates itself from the competitors.
Add comment